Immune Network acquires 85% of Dr Nature in exchange for 7.5 million shares

By E. Janene Geiss

Philadelphia, Jan. 13 - Immune Network Ltd. said Friday that it has acquired an 85% interest in Dr Nature Health Products Inc. in exchange for 7.5 million shares of Immune stock.

Immune said Dr Nature has a natural health product, DRN 11, that it said is proven clinically beneficial in the management of diabetes, according to a company news release.

Immune said it will begin marketing DRN 11, the flagship product developed by Dr Nature over the past eight years. Completed regulatory filing for DRN 11 in Canada allows the company to begin sales immediately, officials said.

Sales into the United States and other markets also will be pursued, officials said.

Preclinical studies have demonstrated that DRN 11 sensitizes the body's response to its own insulin, making it work more efficiently by increasing insulin binding and internalization, officials said. As a result of better use of insulin, muscle cell glucose uptake is increased, officials said.

The benefits against all diabetes symptoms and complications have been demonstrated through three DRN 11 clinical studies, officials said.

In the DRN 11 clinical studies, reductions in the range of 15% to 20% in blood sugar levels have complemented a noted quality-of-life benefit with no side effects and an overall improvement in the well-being and general health of the study participants, officials said.

The company said it believes DRN 11 is an excellent supplement compound for use alongside prescription medications, such as the $800 million drug Metformin.

Diabetes is the third leading cause of death in the United States with an economic cost of more than $100 billion per year and affects 18.2 million people with an estimated 15 million not yet diagnosed, the company said.

Immune, based in Vancouver, B.C., calls itself a "biotech merchant developer." The company said its mission is to capture undervalued drug discovery projects, add value through investment and hard work and to divest profitably through sale, licenses or spin-off company creation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.